Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
7(100.0%)
7Total
Phase 1(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07421778Phase 1Recruiting

A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants

Role: lead

NCT06714396Phase 1Completed

A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALS

Role: lead

NCT05633459Phase 1Active Not Recruiting

A Study Evaluating the Safety and Tolerability of QRL-201 in ALS

Role: lead

NCT06877624Phase 1Completed

A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants

Role: lead

NCT06681441Phase 1Completed

A 3-way Cross-over Study on the Effects of QRL-101 on Transcranial Magnetic Stimulation and Nerve Excitability in Healthy Participants

Role: lead

NCT06532396Phase 1Completed

A Study Evaluating Multiple Ascending Doses of QRL-101 in Healthy Participants

Role: lead

NCT05667779Phase 1Completed

A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants

Role: lead

All 7 trials loaded